Jefferies Initiates Coverage of Absci Corporation with Buy Rating
Jefferies analyst Andrew Tsai has initiated coverage on Absci Corporation with a buy rating and a price target of $14.
Stocks · News reference
Needham Reiterates Buy on Absci, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Absci to Participate in Upcoming Investor Conferences
Absci Corporation announced its participation in three upcoming healthcare investor conferences scheduled for November and December 2026.
Keybanc Maintains Overweight on Absci, Raises Price Target to $20
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $16 price target.
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities
A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.